SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin trades higher on the bourses

12 Apr 2017 Evaluate

Lupin is currently trading at Rs. 1429.50, up by 1.00 points or 0.07% from its previous closing of Rs. 1428.50 on the BSE.

The scrip opened at Rs. 1434.00 and has touched a high and low of Rs. 1434.00 and Rs. 1408.55 respectively. So far 26486 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1750.00 on 29-Jul-2016 and a 52 week low of Rs. 1383.50 on 09-Nov-2016.

Last one week high and low of the scrip stood at Rs. 1465.00 and Rs. 1398.80 respectively. The current market cap of the company is Rs. 64686.13 crore.

The promoters holding in the company stood at 46.69%, while Institutions and Non-Institutions held 41.24% and 12.06% respectively.

Lupin has received final approval for its Bupropion Hydrochloride Extended-Release tablets USP (XL), 150 mg and 300 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Wellbutrin XL tablets, 150 mg and 300 mg. Wellbutrin XL tablets had US sales of $755 million, as per IMS MAT December 2016.

Lupin’s Bupropion Hydrochloride Extended-Release tablets USP (XL), 150 mg and 300 mg are the AB rated generic equivalent of Valeant Pharmaceuticals North America, LLC’s Wellbutrin XL tablets, 150 mg and 300 mg. It is indicated for the treatment of major depressive disorder (MDD) and prevention of seasonal affective disorder (SAD) in adults.

Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×